ElectroCore's Shares Are Trading Higher After Australia Ok'd Vagus Nerve Stimulator For Headaches

The Australian Therapeutic Goods Administration has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products, including a non-invasive vagus nerve stimulator (nVNS) for primary headache disorders.

• Concurrently, the company has entered into an agreement with Medistar2 PTY Limited, whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire nVNS in Australia.

• The initial term of the agreement is three years.

• Medistar, an independent medical device distributor, will officially launch the gammaCore Sapphire at the 2021 ANZHS Headache Annual Scientific Meeting, held on March 13-14.

• Last week, the company completed enrollment in a study evaluating the effect of nVNS on respiratory symptoms due to COVID-19.

• Price Action: ECOR shares surged 58% at $3.43 in premarket trading on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• ElectroCore Concludes Enrollment In COVID-19 Study Evaluating Vagus Nerve Stimulation

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.